Tiziana Life Sciences Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.12next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 10th Joint ACTRIMS/ECTRIMS Meeting Presentation (Toronto) | 31 Oct 2026 |
Monitoring Framework
Key Performance Indicators
INFORM-MS Phase 2a Trial Patient Enrollment Quarterly48.0
Expanded Access Program Patient Count (na-SPMS) Quarterly14
Watch Items
- INFORM-MS Phase 2a Topline Data ReadoutTrigger: Late Q3 2026Action: Evaluate efficacy endpoints (PET microglial activation, MRI, clinical fatigue scores) and safety profile to determine Phase 3 readiness.
- Cash Runway and Going Concern RiskTrigger: Cash balance falling below $3.0 millionAction: Assess capital-raising activities, including ATM issuances, registered direct offerings, or strategic partnerships to fund ongoing trials.
Research as of 20 Jun 2026